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J PIntroduction: Although fortiﬁcation of food with folic acid has been calculated to be cost saving in
the U.S., updated estimates are needed. This analysis calculates new estimates from the societal
perspective of net cost savings per year associated with mandatory folic acid fortiﬁcation of enriched
cereal grain products in the U.S. that was implemented during 1997–1998.
Methods: Estimates of annual numbers of live-born spina biﬁda cases in 1995–1996 relative to
1999–2011 based on birth defects surveillance data were combined during 2015 with published
estimates of the present value of lifetime direct costs updated in 2014 U.S. dollars for a live-born
infant with spina biﬁda to estimate avoided direct costs and net cost savings.
Results: The fortiﬁcation mandate is estimated to have reduced the annual number of U.S.
live-born spina biﬁda cases by 767, with a lower-bound estimate of 614. The present value of mean
direct lifetime cost per infant with spina biﬁda is estimated to be $791,900, or $577,000 excluding
caregiving costs. Using a best estimate of numbers of avoided live-born spina biﬁda cases,
fortiﬁcation is estimated to reduce the present value of total direct costs for each year’s birth cohort
by $603 million more than the cost of fortiﬁcation. A lower-bound estimate of cost savings using
conservative assumptions, including the upper-bound estimate of fortiﬁcation cost, is $299 million.
Conclusions: The estimates of cost savings are larger than previously reported, even using conservative
assumptions. The analysis can also inform assessments of folic acid fortiﬁcation in other countries.
(Am J Prev Med 2016;50(5S1):S74–S80) Published by Elsevier Inc. on behalf of American Journal of Preventive
Medicine. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionPericonceptional folic acid intake protects againsttwo neural tube defects (NTDs), spina biﬁda andanencephaly.1,2 The U.S. Food and Drug Admin-
istration (FDA) mandated that cereal grain products
labeled as enriched after 1997 be fortiﬁed with synthetic
folic acid at a concentration of 140 mg per 100 g,3 whichtional Center on Birth Defects and Developmental Dis-
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is an open access article under the CC BY-NCcontributed to a 36% reduction of NTDs between 1996 and
2006.4 This article reports updated estimates of economic
impacts in order to conﬁrm the value of this policy, inform
other potential mandates, and inform policy analyses for
other countries considering food fortiﬁcation.
Economic evaluation ﬁndings can help inform policy
decisions about the funding of interventions for which
evidence of effectiveness can be demonstrated.5 Prospec-
tive analyses of hypothetical beneﬁts based on the
modeling of expected health outcomes should be com-
plemented by retrospective analyses of observed out-
comes after a policy has been in place. Three prospective
analyses projected 3%–10% reductions in NTDs from the
FDA mandate based on models that assumed a threshold
intake to reduce NTD risk.6–8 The actual reductions in
NTDs following fortiﬁcation costs were much larger,
consistent with a dose–response inverse association of
NTD risk with red blood cell folate concentration.9–11
Annual births with spina biﬁda or anencephaly werer Inc. on behalf of American Journal of Preventive Medicine. This
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and 1998–1999.12 It was projected that fortiﬁcation
resulted in annual direct cost savings of $143 million in
2002 U.S. dollars, mostly from fewer spina biﬁda cases.12
This analysis was conducted during 2015 and updates
cost savings estimates that were published in 200512 for
changes in costs, inﬂation, and survival; caregiving time
costs; and more recent prevalence estimates. Unlike the
previous study, estimates exclude both stillbirths and
anencephaly, which is lethal after birth. Results are
presented for both a base-case analysis in which all
parameters are set to likely values and a worst-case
scenario in which parameters are set to values that result
in conservative estimates of cost savings.
Methods
Avoided Live-born Spina Biﬁda Cases
Base-case estimates of the reduction in spina biﬁda cases come from a
2015 Centers for Disease Control and Prevention (CDC) analysis of
National Birth Defects Prevention Network data for 1995–1996 and
1999–2011. The prevalence of spina biﬁda among live births, stillbirths,
and fetal deaths atZ20 weeks registered in eight systems with prenatal
ascertainment was reported to have decreased from 6.5 per 10,000 live
births pre-fortiﬁcation to 4.0 per 10,000 live births post-fortiﬁcation.13
For the years 2004–2006, the ratio of live-born cases to all cases was
0.77 in three sites.14 Applying this ratio to all spina biﬁda cases, the
frequency of live-born cases decreased from 5.04 to 3.10 per 10,000
births, a reduction of 1.94 cases per 10,000 live births. This reduction in
birth prevalence, multiplied by 3,952,841 births in 2012,15 yields an
estimated 767 annual affected births avoided as a result of fortiﬁcation.
To calculate a lower-bound estimate of effectiveness, the
number of live-born cases during 1995–1996 was lowered by 5%,
to allow for a possibility of a greater proportional decrease in
outcomes other than live birth following fortiﬁcation. That implies
667 live-born cases avoided each year, which is a 13% lower
estimate of effectiveness.
Ready-to-eat (RTE) breakfast cereals accounted for approximately
4.4% of average red blood cell folate concentration among non-
pregnant U.S. women aged 12–49 years during 2007–2012 (calcu-
lations available on request).16 RTE cereals are not subject to
mandatory fortiﬁcation with folic acid but may be voluntarily enriched
with folic acid up to a limit of 400 mg per serving set by FDA in a food
additives standard adopted in 1996.17 Mean red blood cell folate
concentration among U.S. women aged 15–44 years rose by 54.5%
between 1988–1994 and 1999–2006.18,19 Dividing 4.4% by 54.5%
suggests that as much as 8% of the reduction in NTDs following
fortiﬁcation might have been due to voluntary fortiﬁcation of RTE
cereals, which followed the 1996 FDA rule making. The lower-bound
estimate of the averted number of live-born cases attributed to the
mandatory folic acid fortiﬁcation component of the FDA policy was
reduced by 8%, to 614.Direct Costs for Live-born Spina Biﬁda Cases
This analysis follows U.S. cost-effectiveness analysis (CEA) guide-
lines in using the “societal” perspective and estimating avoidedMay 2016direct costs.20 Direct costs include the difference in both medical
and nonmedical services required by individuals with spina biﬁda
and unaffected individuals. In addition, direct costs assessed from
the societal perspective include costs incurred by families, which,
according to U.S. guidelines, include the opportunity cost of time
spent by unpaid family caregivers.20 Two previous U.S. CEAs of
folic acid interventions incorporated caregiver time costs.7,21
However, because caregiver time costs are excluded from direct
costs by some analysts,22 estimates of cost savings that exclude
caregiver time costs are also reported.
Estimates of per-person medical costs were adapted from an
incidence-based cost-of-illness analysis of lifetime costs for
individuals with spina biﬁda23,24 using ﬁndings from a subse-
quent analysis of claims data for adults with spina biﬁda.21,25 The
present estimates incorporate improvements in survival among
children and adolescents with spina biﬁda26; survival probabil-
ities beyond age 19 years were assumed to be the same as in the U.
S. population. All costs were adjusted for inﬂation to 2014 U.S.
dollars (Table 1).
The estimate of unpaid caregiver time costs comes from a survey
in Arkansas during 2001–2002 of annual hours of paid work of
primary parental caregivers of children and adolescents with spina
biﬁda and demographically similar parents in the general pop-
ulation.28 That study estimated that each live-born spina biﬁda
case had a discounted present value of avoided lost parental
economic output that of approximately $159,000 in 2005 dollars,28
which was adjusted to 2014 dollars (Table 1) and for increased
child survival.
The lifetime direct cost of a live-born spina biﬁda case in 2014
dollars (rounded to the nearest $100) is $791,900, comprising
$513,500 in medical costs, $63,500 in developmental services and
special education costs, and $214,900 in caregiver time costs
(Table 1). Direct costs excluding caregiver time costs amount to
approximately $577,000.Implications of Changes in Composition of Spina
Biﬁda Births
Average cost per live-born spina biﬁda case may have changed
with fortiﬁcation, which was accompanied by increases in the
proportion of cases of non-isolated spina biﬁda29,30 and decreases
in the proportion of cases with upper-level (cervical or thoracic)
lesions.30,31 Estimates of costs for subtypes of spina biﬁda,
including by lesion level, were not available. Post-infancy hospital-
ization costs for children with spina biﬁda who have another major
birth defect are roughly 1.5 times greater than for isolated spina
biﬁda (E Radcliff, University of South Carolina, personal commu-
nication, 2014). Upper-level lesions are associated with higher
parental time costs. If death during childhood is more common in
upper-level spina biﬁda cases, as has been suggested,7 fortiﬁcation
may have contributed to a disproportionate reduction in infant
and child deaths. For a sensitivity analysis, the estimates of direct
medical and service costs were adjusted downward by 10% to
reﬂect the possible impacts of more than proportional reduction in
deaths, as spina biﬁda–associated costs associated with those
infants who survive as a result of fortiﬁcation should be subtracted
from averted costs of live-born cases assuming no difference in
survival rates.
Table 1. Parameter Estimates and Sources
Parameter Point estimate Sources
Prevalence of spina biﬁda in 1995–1996 in systems with prenatal
ascertainment
6.5 per 10,000 births 13
Prevalence of spina biﬁda in 1999–2011 in systems with prenatal
ascertainment
4.0 per 10,000 births 13
Percentage of live births among spina biﬁda cases in systems
with prenatal ascertainment during 2004–2006
77.0% 14
Annual births in 2012 3,952,841 15
Ready-to-eat breakfast cereals share of average RBC folate
concentration among non-pregnant U.S. women aged 12–49
years during 2007–2012
4.4% 16
Increase in mean RBC folate concentration among U.S. women
aged 15–44 years between 1988–1994 and 1999–2006
54.5% 18
Base-case fortiﬁcation cost $4 million Expert opinion
Worst-case fortiﬁcation cost $20 million Expert opinion
Cost components for live-born infants with spina biﬁda (present value, 2014 U.S. dollars, rounded to nearest 100)
Medical $513,500a 25,27
Special education and developmental services $63,500b 24
Parental time cost $214,900c 28
Total $791,900 —
Excluding caregiver time cost $577,000 —
aAdjusted for inﬂation using the Bureau of Economic Analysis Personal Consumption Expenditures health care deﬂator, available at www.bea.gov/,
Table 2.3.4, Price Indexes for Personal Consumption Expenditures by Major Function (series DHLTRG).
bAdjusted for inﬂation using the Bureau of Labor Statistics Employment Cost Index for state and local government employees employed in educational
services, available from www.bls.gov/web/eci/echistrynaics.pdf, Table 7.
cAdjusted for inﬂation using the Bureau of Labor Statistics Employment Cost Index for all civilian workers, available from www.bls.gov/web/eci/
echistrynaics.pdf, Table 4.
RBC, Red blood cell.
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The incremental cost of fortiﬁcation is the product of the quantity
of grain product and the unit cost of adding folic acid to the
premix, which mills use to fortify enriched grain products. The
cost of folic acid was estimated to be $0.10–0.15 per metric ton of
ﬂour in 2013, $0.20–0.30 per metric ton in 2014, and, owing to a
shortage in early 2015, close to $1.00 per ton as of May 2015
(Q Johnson, Quican, Inc., personal communication, 2015). With
roughly 20 million metric tons of enriched foods, the estimated
total cost of folic acid fortiﬁcation each year was approximately
$2–3 million in 2013, $4–6 million in 2014, and $20 million in
2015. Those ﬁgures compare with previous estimates of $3–4
million.7,12 The base-case model uses $4 million and the worst-
case scenario assumes $20 million per year.Results
The base-case estimate of the total direct cost averted
each year is $607 million, or $442 million excludingcaregiver time costs (Table 2). That assumes 767 averted
live-born spina biﬁda cases and a constant cost per live-
born case. With a lower-bound estimate of 614 live-born
cases averted by mandatory fortiﬁcation and the cost per
live-born case lowered by 10%, the “worst-case” estimate
of avoided direct costs is $438 million overall or $319
million excluding parental caregiver time costs.
The base-case estimate of net cost savings, after sub-
tracting the estimate of $4 million incremental cost of folic
acid fortiﬁcation from the estimate of averted direct costs,
is $603 million including the lost value of parental
employment due to added caregiving responsibilities as
is recommended, or $438 million excluding caregiver time
costs. Using lower-bound estimates of live-born cases and
costs averted, which exclude parental caregiving costs, and
using the upper bound estimate of $20 million in
fortiﬁcation costs, net cost savings in the worst-case
scenario is estimated to be $299 million per year.www.ajpmonline.org
Table 2. Summary of Annual Averted Direct Costs and Cost Savings (2014 U.S. dollars)
Scenario
Number of
live births
averted
Total direct cost per birth with
spina biﬁda averted (nearest
$100)
Total direct cost
averted (nearest
$100,000)
Cost savings (reduction in
direct costs, nearest
$100,000)
Base-
case
767 791,900 607.3 million 603.3 million
767 577,000a 442.4 milliona 438.4 milliona
Worst
case
614 712,700 437.5 million 417.5 million
614 519,300a 318.8 milliona 298.8 milliona
aExcluding caregiver time costs
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Based on estimates presented here, fortiﬁcation has had a
larger societal return on investment than previously
estimated. The base-case net cost savings estimate of
$607 million in 2014 dollars is 3.1 times larger than the
previous estimate,12 which is equivalent to $195 million
in 2014 dollars. The increase is explained by three
differences in assumptions. First, the estimate of per-
person incremental medical costs with spina biﬁda is 59%
higher than the previous estimate in inﬂation-adjusted
dollars, based on more complete expenditure data for
adults with spina biﬁda25 and increases in survival among
children with spina biﬁda.26 Second, the base-case
inclusion of caregiver time costs as is recommended in
U.S. CEA guidelines20 raised the per-person direct cost
estimate by 37%. Third, the estimated number of annual
live-born cases of spina biﬁda avoided is 47% larger
compared with the previous analysis. That analysis relied
on published prevalence estimates from passive birth
defects surveillance systems with less complete and
accurate ascertainment compared with active surveil-
lance programs that routinely ascertain prenatally diag-
nosed cases, including fetal deaths.
Exclusion of unpaid caregiving costs from the base-
case analysis reduces the estimate of cost savings.
However, reduction in caregiver time costs is an impor-
tant “spillover” beneﬁt to other family members, and
exclusion of such effects can understate the economic
impact of prevention.32 Even in the worst-case scenario
using estimates that are least favorable to fortiﬁcation,
net cost savings are estimated at almost $300 million per
year. That estimate, which excludes lost parental pro-
ductivity owing to caregiving responsibilities, takes into
account the additional cost of spina biﬁda–associated
care for infants who in the absence of fortiﬁcation would
have died. It has been argued by some that unrelated
lifetime medical costs should also be included for avoided
deaths.33May 2016The base-case estimates of costs savings may be
conservative. In particular, individuals with thoracic or
higher lumbar lesions may not be subject to signiﬁcantly
higher mortality. In a population-based 2001–2002
survey of Arkansas families with children and adoles-
cents with spina biﬁda, 24.5% had upper-level lesions,
which did not vary signiﬁcantly by age.28,34 Unpublished
cross-sectional data from the National Spina Biﬁda
Patient Registry35 indicate that upper-level lesions are
very common among adolescents and adults with spina
biﬁda born prior to 1999 and less common among
younger children (R Valdez on behalf of the CDC
National Spina Biﬁda Patient Registry team, personal
communication, 2014).
Policy Implications
This retrospective analysis ampliﬁes previous U.S. esti-
mates of the economic beneﬁts of mandatory folic acid
fortiﬁcation of cereal grain products labeled as enriched
at the level of 140 mg per 100 g. However, despite that
policy, U.S. Hispanic women with origins in Mexico and
Central America consume fewer fortiﬁed foods and their
children have elevated NTD prevalence.36 Fortifying corn
masa ﬂour (dry alkali-processed maize ﬂour37), which is
disproportionately consumed by less-acculturated
Mexican American women,36 could reduce the number
of cases of NTDs in the U.S. by approximately 40 per year
(range, 0–120).38,39 A CEA of corn masa fortiﬁcation
requires additional modeling, including estimates of the
numbers of avoided live-born spina biﬁda cases as well as
the costs of fortifying corn masa ﬂour.
The ﬁndings presented here could inform policy
analyses for countries considering folic acid fortiﬁcation.
Although fortiﬁcation has variable impacts on NTDs
depending on folate status and NTD prevalence, which
foods are fortiﬁed and at what level, and consumption of
fortiﬁed foods, it has been a success in several coun-
tries.40–44 Incomplete data on costs of care for spina
Grosse et al / Am J Prev Med 2016;50(5S1):S74–S80S78biﬁda can result in conservative estimates of avoided
costs. For example, a CEA of fortiﬁcation in Chile
concluded that fortiﬁcation was cost saving, although
only the subset of surgical repair and rehabilitation costs
through age 22 years were included (present value per
birth of approximately $20,000 in 2007 dollars).45 A
South African CEA calculated cost savings based on
estimated treatment costs during infancy.46 Therefore,
the published estimates of cost savings from fortiﬁcation
in Chile and South Africa were very conservative. A
newly published study estimated the potential cost
savings from a hypothetical fortiﬁcation policy in Ger-
many, which reported that reducing spina biﬁda births
by 40%–50% would save €26–33 million per year in
direct costs.47 That study adjusted the U.S. estimate of
lifetime medical costs used in the present study25 down-
ward by 47% to account for lower healthcare costs in
Germany.Limitations
This analysis has several limitations. First, it relies on
estimates of changes in the birth prevalence of spina
biﬁda from eight surveillance systems located in different
parts of the U.S. It is common not to report SEs or CIs for
birth defects surveillance estimates because ascertain-
ment biases are presumed greater in magnitude than
random errors resulting from sampling variability.48 The
analysis used estimates from surveillance systems with
prenatal ascertainment to minimize under-ascertain-
ment.14 Although the resulting estimates of numbers of
total cases with spina biﬁda are more robust than
previous estimates, uncertainty in these parameter esti-
mates was taken into account through sensitivity analyses
to develop lower-bound or worst-case estimates.
The base-case analysis attributed all of the decline in
live-born cases of spina biﬁda and associated direct costs
to fortiﬁcation. The assumption that the change in
prevalence was not inﬂuenced by increased consumption
of folic acid supplements is consistent with the absence of
change in the use of folic acid–containing supplements
by U.S. adults during the study period.49 The assumption
that changes in the frequency of elective termination of
fetuses with spina biﬁda did not contribute to the
decrease in the prevalence of live-born cases in the
present analysis is consistent with the ﬁnding that
the decrease in total spina biﬁda cases between 1995–
1996 and 1998–2006 was greater in systems that included
prenatal ascertainment of terminations and early fetal
deaths than in systems without prenatal ascertai-
nment.13,50
Other potential limitations include the exclusion of
non-NTD health outcomes. CEAs should include allhealth outcomes for which there is evidence of impact,
both beneﬁts and harms. Prospective economic assess-
ments of fortiﬁcation projected that folic acid fortiﬁca-
tion could “mask” vitamin B-12 deﬁciency, delay
diagnosis, and adversely affect the neurologic status of
older adults who have low vitamin B status.6,7,51 How-
ever, post-fortiﬁcation empirical evidence did not bear
out those fears.44,52–54 Likewise, subsequent concerns
that additional folic acid might increase the incidence of
colorectal cancer were not conﬁrmed.55,56
Folic acid might also have had other favorable out-
comes. In U.S. and Canadian data, the incidence of one
rare cancer, Wilms tumor, decreased by 20%–26%
following fortiﬁcation.57,58 By contrast, although U.S.
folic acid fortiﬁcation was followed by signiﬁcant reduc-
tions in selected non-NTD birth defects,59 no signiﬁcant
reductions were observed in other countries.42,60 There is
also a possibility, not conﬁrmed, that folic acid fortiﬁca-
tion might have reduced the risk of stroke; an epidemio-
logic analysis found a roughly 10 percentage point
additional reduction in stroke mortality in the U.S.
during 1998–2002.61 Folic acid supplements, at higher
doses, have been reported to reduce the occurrence of
stroke by approximately 10% in areas with low folic acid
intakes,62,63 and a recent trial found that folic acid
supplements (800 µg per day) signiﬁcantly reduced the
risk of ﬁrst stroke among Chinese adults with hyper-
tension.64
These ﬁndings are conservative as a measure of the
economic beneﬁt of folic acid fortiﬁcation because they
do not include either intangible beneﬁts such as knowing
that women and infants are protected from harm or the
avoided “indirect” costs of lost productivity resulting
from premature death and disability. Previous analyses
that used the present value of average lifetime produc-
tivity to value averted deaths reported that the total
economic beneﬁt of NTD prevention is much larger than
the reduction in direct costs alone.12,23 However, pro-
ductivity measures understate the economic beneﬁt of
avoided deaths65 and do not capture the economic
beneﬁts of avoided pregnancy outcomes other than live
birth.66
Conclusions
Fortiﬁcation with folic acid is effective in preventing
NTDs and saves hundreds of millions of dollars each
year. The present estimates of cost savings are larger than
in previous analyses owing to more complete counting of
averted cases, costs, and inﬂation. Economic evaluation
should form part of an iterative process in which
assumptions are reassessed and updated as needed.
Retrospective evaluations previously conﬁrmed that thewww.ajpmonline.org
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assumed prior to fortiﬁcation. The new evidence pre-
sented here warrants consideration by decision makers in
other parts of the world who might consider fortiﬁcation
policies to reduce the occurrence of NTDs.Publication of this article has been sponsored by the Centers
for Disease Control and Prevention (CDC), Ofﬁce of the
Associate Director for Policy. The ﬁndings and conclusions
in this report are those of the authors and do not necessarily
represent the ofﬁcial position of CDC.
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